Cellular pathology of experimental colitis induced by trinitrobenzenesulphonic acid (TNBS): Protective effects of recombinant human interleukin-11

被引：9

作者：

Pfeiffer C.J. ^{[1
]}

Sato S. ^{[1
]}

Qiu B.S. ^{[1
]}

Keith J.C. Jr. ^{[1
]}

Evangelista S. ^{[1
]}

机构：

[1] Dept. Biomedical Sciences/Pathobiol., VMRCVM, Virginia Polytechnic Institute, Blacksburg

来源：

InflammoPharmacology | 1997年 / 5卷 / 4期

关键词：

Colitis; Gastrointestinal; Interleukin-11; Ultrastructure;

D O I：

10.1007/s10787-997-0033-6

中图分类号：

学科分类号：

摘要：

The objective of this study was to elucidate colonic mucosal ultrastructural effects of trinitrobenzenesulphonic acid (TNBS) with and without co-administration of recombinant human interleukin-11 (rhIL-11). Using a standard colitis model (ir alcoholic TNBS), rats were sacrificed at 3-14 days after TNBS. Co-administration of rhIL-11 (100, 300 or 1000 μg/kg sc) was given for protection, and controls received saline or alcohol ir, or rhIL-11 sc alone. Transmission electron microscopy revealed that early TNBS-induced cytopathology was primarily in absorptive cells, changes which occurred prior to goblet cell damage. Progressive cellular changes included vacuolization and increased multivesicular bodies in cell apices, disconfiguration of microvilli, enlarged Golgi apparatuses, enlargement of basal intercellular spaces, and eventual desquamation of epithelium and apical bursting. Organelle damage preceded surface changes and resembled ultrastructural changes reported for human ulcerative colitis. The principal effect of rhIL-11 was apparent massive release of mucus from goblet cells, filling the colonic crypts, and suggesting a mode of its protection.

引用

页码：363 / 381

页数：18

共 35 条

[1]

MacPherson B, Pfeiffer CJ, Experimental colitis, Digestion, 14, pp. 424-52, (1976)

[2]

Elson CO, Sartor RB, Tennyson GS, Riddell RH, Experimental models of inflammatory bowel disease, Gastroenterology, 109, pp. 1344-67, (1995)

[3]

Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL, Hapten-induced model of chronic inflammation and ulceration in the rat colon, Gastroenterology, 96, pp. 795-803, (1989)

[4]

Rachmilewitz D, Simon PL, Schwartz LW, Griswold DE, Fondacano JD, Wasserman MA, Inflammatory mediators of experimental colitis in rats, Gastroenterology, 97, pp. 326-37, (1989)

[5]

Zeitlin IJ, Smith AN, Mobilization of tissue kallikreins in inflammatory diseases of the colon, Gut., 14, pp. 133-8, (1973)

[6]

Ekakim R, Karmeli F, Razin E, Rachmilewitz D, Role of platelet-activating factor in ulcerative colitis, Gastroenterology, 95, pp. 1167-72, (1988)

[7]

Kishimoto S, Kobayashi H, Shimizu S, Changes of colonic vasoactive intestinal peptide and cholinergic activity in rats with chemical colitis, Dig Dis Sci., 37, pp. 1729-37, (1992)

[8]

Keshavarzian A, Sedghi S, Kanofsky J, Excessive production of reactive oxygen metabolites by inflamed colon: analysis by chemiluminescence probe, Gastroenterology, 103, pp. 177-85, (1992)

[9]

Ligumsky M, Simon PL, Karmeli F, Rachmilewitz D, Role of interleukin 1 in inflammatory bowel disease-enhanced production during active disease, Gut., 31, pp. 686-9, (1990)

[10]

Cominelli F, Nast CC, Duchini A, Lee M, Recombinant interleukin-1 receptor antagonist blocks the pro-inflammatory activity of endogenous interleukin-1 in rabbit immune colitis, Gastroenterology, 103, pp. 65-71, (1992)

← 1 2 3 4 →